Nanomaterial risks are often considered in terms of novel material behaviours. But, as Andrew D. Maynard explains, does this framing end up obscuring some risks, while overplaying others?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Antioxidant hepatic lipid metabolism can be promoted by orally administered inorganic nanoparticles
Nature Communications Open Access 20 June 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hansen, S. F., Maynard, A., Baun, A., Tickner, J. A. & Bowman, D. M. in Late Lessons from Early Warnings: Science, Precaution, Innovation 562–591 (European Environment Agency, 2013).
Maynard, A. D., Warheit, D. & Philbert, M. A. Toxicol. Sci. 120, S109–S129 (2011).
Maynard, A. D. in Nanotechnology Environmental Health and Safety: Risks, Regulation, and Management (Micro and Nano Technologies) 2nd edn (eds Hull, M. & Bowman, B. M.) 339–365 (William Andrew, 2014).
Donaldson, K. & Poland, C. A. Curr. Opin. Biotechnol. 24, 724–734 (2013).
Nohynek, G. J., Lademann, L., Ribaud, C. & Roberts, M. S. Crit. Rev. Toxicol. 37, 251–277 (2007).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maynard, A. Is novelty overrated?. Nature Nanotech 9, 409–410 (2014). https://doi.org/10.1038/nnano.2014.116
Published:
Issue Date:
DOI: https://doi.org/10.1038/nnano.2014.116